Pathophysiology

Martina Porter (Harvard Medical School, Boston, Massachusetts, USA) shares her opinion on the remaining unknowns in HS pathophysiology. View transcript.

Martina Porter shares her thoughts on presentations at EADV 2024 addressing cardiometabolic risks for people with HS. View transcript.

Research presented in a late-breaking session compared cardiometabolic risk in 61 patients with a family history of hidradenitis suppurativa (HS) and 175 with sporadic HS.

Suzan Al-Gburi (University Hospital Cologne, Germany) reported that participants with a family history were a significant two to three times more likely to have hyperlipidaemia or cardiovascular disease, despite having slightly less severe disease than those with sporadic HS.

She suggested this may be due to people with a family history presenting later after symptom onset and self-managing in the meantime.

In support of this was a poster presentation showing that greater subclinical atherosclerosis severity in 84 people with HS was associated with longer HS duration and the presence of structural damage. The researchers highlighted inflammation as the likely underlying factor for both conditions.

Pathophysiology

What role do cells, mediators, and bacteria play in HS pathophysiology? Catch up on key updates from EHSF 2024, with an expert interview featuring Dr Philippe Guillem (Clinique du Val d’Ouest, Ecully, France).

Dr Guillem discusses updates in pathophysiology, including involvement of fibroblasts and the interaction between bacteria and the immune system in HS. View transcript.